Galera Therapeutics Analyst Ratings
Galera Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Galera Therapeutics (GRTX) is trading at is $2.75, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/17/2023 | 118.18% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/22/2023 | 118.18% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 02/21/2023 | 118.18% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 02/16/2023 | 154.55% | B of A Securities | $2 → $7 | Upgrades | Underperform → Buy |
| 02/16/2023 | 263.64% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/27/2022 | -27.27% | B of A Securities | → $2 | Downgrades | Neutral → Underperform |
| 12/20/2021 | 627.27% | Citigroup | $11 → $20 | Maintains | Buy |
| 12/15/2021 | 263.64% | HC Wainwright & Co. | → $10 | Upgrades | Neutral → Buy |
| 12/15/2021 | 445.45% | BTIG | → $15 | Upgrades | Neutral → Buy |
| 10/20/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/19/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/16/2020 | 445.45% | Credit Suisse | $9 → $15 | Upgrades | Neutral → Outperform |
| 12/07/2020 | 445.45% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 11/11/2020 | 227.27% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 07/29/2020 | 190.91% | Credit Suisse | $14 → $8 | Maintains | Neutral |
| 12/02/2019 | 990.91% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 12/02/2019 | 445.45% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 12/02/2019 | 627.27% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 409.09% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/17/2023 | 118.18% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 03/22/2023 | 118.18% | HC Wainwright公司 | $10→$6 | 维护 | 买 |
| 02/21/2023 | 118.18% | 派珀·桑德勒 | →$6 | 开始承保 | →超重 |
| 02/16/2023 | 154.55% | B of A证券 | $2→$7 | 升级 | 表现不佳的→收购 |
| 02/16/2023 | 263.64% | HC Wainwright公司 | →$10 | 重申 | →购买 |
| 2022年05月27日 | -27.27% | B of A证券 | →$2 | 评级下调 | 中性→表现不佳 |
| 12/20/2021 | 627.27% | 花旗集团 | $11→$20 | 维护 | 买 |
| 2021年12月15日 | 263.64% | HC Wainwright公司 | →$10 | 升级 | 中性→购买 |
| 2021年12月15日 | 445.45% | BTIG | →$15 | 升级 | 中性→购买 |
| 10/20/2021 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 10/19/2021 | - | BTIG | 评级下调 | 购买→中性 | |
| 12/16/2020 | 445.45% | 瑞士信贷 | $9→$15 | 升级 | 中性→表现优异 |
| 12/07/2020 | 445.45% | HC Wainwright公司 | →$15 | 开始承保 | →购买 |
| 11/11/2020 | 227.27% | 瑞士信贷 | $8→$9 | 维护 | 中性 |
| 07/29/2020 | 190.91% | 瑞士信贷 | $14→$8 | 维护 | 中性 |
| 2019年2月12日 | 990.91% | BTIG | →$30 | 开始承保 | →购买 |
| 2019年2月12日 | 445.45% | B of A证券 | →$15 | 开始承保 | →购买 |
| 2019年2月12日 | 627.27% | 花旗集团 | →$20 | 开始承保 | →购买 |
| 2019年2月12日 | 409.09% | 瑞士信贷 | →$14 | 开始承保 | →中性 |
What is the target price for Galera Therapeutics (GRTX)?
Galera治疗公司(GRTX)的目标价格是多少？
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by HC Wainwright & Co. on July 17, 2023. The analyst firm set a price target for $6.00 expecting GRTX to rise to within 12 months (a possible 118.18% upside). 5 analyst firms have reported ratings in the last year.
伽莱拉治疗公司(纳斯达克代码：GRTX)的最新目标价是由HC Wainwright&Co.于2023年7月17日报道的。这家分析公司将目标价定为6美元，预计GRTX将在12个月内上涨至(可能上涨118.18)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Galera Therapeutics (GRTX)?
Galera治疗公司(GRTX)的最新分析师评级是多少？
The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by HC Wainwright & Co., and Galera Therapeutics reiterated their buy rating.
加莱拉治疗公司(纳斯达克代码：GRTX)的最新分析师评级是由HC Wainwright&Co.提供的，加莱拉治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Galera Therapeutics (GRTX)?
Galera治疗公司(GRTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Galera治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Galera治疗公司的上一次评级是在2023年7月17日提交的，所以你应该预计下一次评级将在2024年7月17日左右的某个时候提供。
Is the Analyst Rating Galera Therapeutics (GRTX) correct?
分析师对Galera Treateutics(GRTX)的评级正确吗？
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Galera Therapeutics (GRTX) is trading at is $2.75, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Galera治疗公司(GRTX)评级被重申，目标价在0.00美元至6.00美元之间。Galera治疗公司(GRTX)目前的交易价格为2.75美元，在分析师的预测范围内。